GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taysha Gene Therapies Inc (NAS:TSHA) » Definitions » PS Ratio

Taysha Gene Therapies (Taysha Gene Therapies) PS Ratio : 27.29 (As of May. 21, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Taysha Gene Therapies PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Taysha Gene Therapies's share price is $2.975. Taysha Gene Therapies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.11. Hence, Taysha Gene Therapies's PS Ratio for today is 27.29.

Warning Sign:

Taysha Gene Therapies Inc stock PS Ratio (=28.35) is close to 1-year high of 28.35

The historical rank and industry rank for Taysha Gene Therapies's PS Ratio or its related term are showing as below:

TSHA' s PS Ratio Range Over the Past 10 Years
Min: 4.13   Med: 11.43   Max: 52.27
Current: 27.27

During the past 5 years, Taysha Gene Therapies's highest PS Ratio was 52.27. The lowest was 4.13. And the median was 11.43.

TSHA's PS Ratio is ranked worse than
71.6% of 1000 companies
in the Biotechnology industry
Industry Median: 9.14 vs TSHA: 27.27

Taysha Gene Therapies's Revenue per Sharefor the three months ended in Mar. 2024 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.11.

Warning Sign:

Taysha Gene Therapies Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Taysha Gene Therapies was -7.60% per year.

Back to Basics: PS Ratio


Taysha Gene Therapies PS Ratio Historical Data

The historical data trend for Taysha Gene Therapies's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taysha Gene Therapies PS Ratio Chart

Taysha Gene Therapies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
- - - 39.65 13.31

Taysha Gene Therapies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.76 4.26 16.37 13.31 26.33

Competitive Comparison of Taysha Gene Therapies's PS Ratio

For the Biotechnology subindustry, Taysha Gene Therapies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taysha Gene Therapies's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's PS Ratio distribution charts can be found below:

* The bar in red indicates where Taysha Gene Therapies's PS Ratio falls into.



Taysha Gene Therapies PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Taysha Gene Therapies's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.975/0.109
=27.29

Taysha Gene Therapies's Share Price of today is $2.975.
Taysha Gene Therapies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.11.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Taysha Gene Therapies  (NAS:TSHA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Taysha Gene Therapies PS Ratio Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Taysha Gene Therapies (Taysha Gene Therapies) Business Description

Traded in Other Exchanges
N/A
Address
3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
Executives
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Alison S Long director KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kamran Alam officer: Chief Financial Officer 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Sean P. Nolan director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Phillip B. Donenberg director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Session R.a. Ii 10 percent owner C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Sukumar Nagendran director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Astellas Pharma Inc. 10 percent owner 2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411
Audentes Therapeutics, Inc. 10 percent owner 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Suyash Prasad officer: CMO and Head of R&D C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104
Laura Sepp-lorenzino director C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Kathleen Reape director C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235

Taysha Gene Therapies (Taysha Gene Therapies) Headlines

From GuruFocus

Taysha Gene Therapies Announces Executive Leadership Changes

By Value_Insider Value_Insider 12-17-2022